The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these ...

14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

BIIB is set to unveil its fiscal Q1 2025 earnings ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports.

Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.